Abbott has announced the achievement of a significant regulatory milestone with the receipt of the CE Mark for its Amulet 360 Left Atrial Appendage (LAA) closure system, signaling a new phase of competition in the rapidly expanding structural heart market. The approval allows the medical device giant to market its latest generation LAA occlusion technology across Europe, providing a sophisticated alternative for patients with atrial fibrillation (AFib) who are at high risk of stroke. This regulatory success follows the presentation of positive clinical data from the VERITAS study and comes as Abbott prepares for a similar commercial launch in the United States, following its submission to the Food and Drug Administration (FDA) earlier this year.
The Amulet 360 represents a strategic evolution of Abbott’s structural heart portfolio, specifically designed to address the clinical challenges associated with sealing the left atrial appendage—a small, ear-shaped pouch in the heart where blood can pool and form clots in patients with AFib. By permanently sealing this appendage, the Amulet 360 offers a mechanical solution to stroke prevention, potentially eliminating the need for long-term oral anticoagulants, which many patients cannot tolerate due to bleeding risks.
Clinical Necessity and the Mechanics of LAA Closure
Atrial fibrillation is the most common sustained heart rhythm disorder worldwide, affecting millions of individuals. The condition is characterized by an irregular and often rapid heart rate that can lead to blood clots, stroke, heart failure, and other heart-related complications. In patients with non-valvular AFib, more than 90% of stroke-causing clots that originate in the heart are formed in the left atrial appendage.
While blood thinners (anticoagulants) have long been the standard of care for stroke prevention in AFib patients, they carry significant risks of internal bleeding. For patients with high-risk occupations, a history of gastrointestinal bleeding, or those prone to frequent falls, long-term medication is often contraindicated. LAA closure devices have emerged as a vital alternative, offering a "one-and-done" procedure performed via a minimally invasive catheter-based approach.
The Amulet 360 builds upon the foundational technology of the original Amplatzer Amulet. The device utilizes a "dual-seal" design, consisting of a lobe that anchors within the appendage and a disc that covers the opening (the ostium) to ensure a complete seal. This design is intended to provide immediate and comprehensive closure, reducing the risk of "peri-device leaks," which are small gaps that can still allow clots to escape into the bloodstream.
The VERITAS Study and Clinical Validation
The European regulatory approval was underpinned by data from the VERITAS study, which was presented at the 2026 AF Symposium. The study was designed to evaluate the safety and effectiveness of the Amulet 360 system in a diverse patient population. According to the data released by Abbott, the device met its primary benchmarks for both safety and efficacy, demonstrating high rates of successful implantation and effective appendage closure.
Clinical investigators noted that the Amulet 360 showed a remarkable ability to adapt to varying LAA anatomies, which can differ significantly from patient to patient. The "seamless implant experience" cited by Abbott CEO Robert Ford refers to the refined delivery system and the device’s ability to be repositioned and recaptured during the procedure, allowing physicians to achieve optimal placement before final deployment. These technical improvements are critical in reducing procedure times and minimizing complications such as pericardial effusion or device embolization.
Market Dynamics and the Battle for Market Share
The LAA closure market is currently valued at approximately $2 billion annually and is projected to experience double-digit growth over the next decade. This growth is driven by an aging global population and an increasing clinical preference for device-based stroke prevention over pharmacological intervention.
Despite the market’s size, it has historically been dominated by a single player. Boston Scientific’s Watchman device currently holds roughly 90% of the market share, a position it has maintained through early entry and iterative product updates. Abbott’s CEO Robert Ford has been transparent about the company’s intentions to disrupt this near-monopoly. During a recent earnings call, Ford emphasized that the Amulet 360 is the "catalyst" needed to capture significant market share.
"My focus, and the team’s focus here, is on market share capture," Ford told investors. "I think this represents a big opportunity for us. Data and feedback from Amulet 360 has been fantastic."
Financial analysts, including Marie Thibault of BTIG, have identified the Amulet 360 as a pivotal product for Abbott’s medical device division. The expectation is that the device will begin to drive substantial revenue growth by 2027 as it gains traction in European markets and clears the final hurdles for U.S. commercialization.
A Crowded Competitive Landscape
While the primary rivalry exists between Abbott and Boston Scientific, other major medical technology firms are also vying for a piece of the LAA treatment market. The landscape has become increasingly crowded as companies recognize the lucrative potential of structural heart interventions:
- Medtronic: The company offers the Penditure LAA exclusion system. Unlike the "plug" style of the Amulet or Watchman, Medtronic’s approach focuses on an exclusion clip, expanding the options available to electrophysiologists and surgeons.
- AtriCure: A long-standing player in the space, AtriCure sells the AtriClip, which is often applied during concomitant cardiac surgeries to manage the LAA.
- Edwards Lifesciences: Known for its dominance in heart valves, Edwards recently received FDA clearance for its own LAA clip device in June, signaling its entry into the competitive fray.
The diversification of technology—ranging from transcatheter plugs to surgical clips—reflects the medical community’s recognition that no single device is perfect for every patient. Abbott’s Amulet 360 aims to lead the transcatheter segment by offering superior sealing capabilities and ease of use for the implanting physician.
Timeline of Development and Regulatory Path
The journey of the Amulet system reflects the long-term investment required in the medical device industry. The original Amplatzer Amulet has been in use in Europe since 2013, providing Abbott with over a decade of real-world data and clinical experience in the region. The device did not receive FDA approval for use in the United States until 2021, at which point it began to slowly chip away at the incumbent’s lead.
The development of the Amulet 360 was initiated to address physician feedback regarding the original system’s profile and delivery mechanism. In May 2026, Abbott completed its submission to the FDA for the Amulet 360, seeking to bring the updated technology to the American market. With the CE Mark now secured, European physicians will have immediate access to the technology, while U.S. providers anticipate a launch potentially in late 2026 or early 2027, pending federal review.
Broader Implications for Healthcare and Patient Outcomes
The advancement of LAA closure technology like the Amulet 360 has broader implications for healthcare systems and patient quality of life. From a health economics perspective, while the initial cost of the device and procedure is high, the long-term savings are significant. By preventing strokes—which often result in expensive emergency care, long-term rehabilitation, or permanent disability—LAA closure can reduce the total cost of care for AFib patients over their lifetime.
Furthermore, for the patients themselves, the ability to discontinue blood thinners is often a life-changing event. Anticoagulants require strict adherence and, in the case of older medications like warfarin, frequent blood monitoring and dietary restrictions. Newer direct oral anticoagulants (DOACs) are easier to manage but still carry a persistent risk of major bleeding events. A successful LAA closure provides peace of mind and physical freedom, particularly for active seniors.
Future Outlook: 2027 and Beyond
As Abbott rolls out the Amulet 360 across Europe, the medical community will be watching closely to see if the "seamless experience" promised by leadership translates into higher adoption rates. The company’s strategy involves not only providing a superior device but also investing in physician training and clinical support to ensure high success rates in the cath lab.
The structural heart sector remains one of the most vibrant areas of medical innovation. With the CE Mark in hand, Abbott is positioned to leverage its global infrastructure to challenge the status quo. The coming years will likely see a "feature war" between Abbott and Boston Scientific, as each company iterates on its design to offer better closure rates, lower complication profiles, and easier delivery.
For investors, the Amulet 360 represents a key pillar of Abbott’s growth strategy. As CEO Robert Ford noted, the feedback from the clinical community has been "fantastic," and if that sentiment holds during the commercial launch, Abbott may well be on its way to reshaping the $2 billion LAA closure market. The success of this device will be a major determinant of Abbott’s ability to sustain its momentum in the medical device sector through the end of the decade.
